ArticlePatient preference and adherence2017
Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center.
Article in Patient preference and adherence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Trial
- Trial
- Short-Course Subcutaneous Immunotherapy With Mannan-Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements.Clinical and translational allergy · 2026Article
- Review
- Identifying Causes of Subcutaneous Immunotherapy Non-Adherence in Patients with Allergic Rhinitis: A Cross-Sectional Study.Patient preference and adherence · 2025Article
- An Overview of Adherence-What It Is and Why It Is Important.The journal of allergy and clinical immunology. In practice · 2024Review
- Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI).The journal of allergy and clinical immunology. Global · 2024Review
- Patient compliance to sublingual immunotherapy for mite-induced allergic rhinitis: A retrospective study.The World Allergy Organization journal · 2024Article
- Sequential model for predicting patient adherence in subcutaneous immunotherapy for allergic rhinitis.Frontiers in pharmacology · 2024Article
- Tolerability and Safety of Sublingual Immunotherapy in Patients with Tree Pollen Allergy in Daily Practice-An Open, Prospective, Non-Interventional Study.Journal of clinical medicine · 2023Article
- Causes of Non-Adherence to Allergen-Specific Immunotherapy: A Foundation towards a Patient-Personalized Approach.Journal of personalized medicine · 2023Review
- [Analysis of adherence and determinants of sublingual immunotherapy in patients with Artemisia pollen-induced allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023Article
- KAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management.Allergy, asthma & immunology research · 2023Review
- ITULAZAXClinical and translational allergy · 2022Article
- Adherence in allergen immunotherapy: Current situation and future implications.Allergologie select · 2022Review
- Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic.The World Allergy Organization journal · 2021Article
- Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma.Patient preference and adherence · 2020Article
- Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study.BioMed research international · 2020Article
- A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.PloS one · 2020Article
- Interactive Network Platform Improves Compliance and Efficacy of Subcutaneous Immunotherapy for Patients with Allergic Rhinitis.Patient preference and adherence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany placebo-controlled studies have demonstrated that allergen immunotherapy (AIT) is an effective therapy for treating allergies. Both commonly used routes, subcutaneous (SCIT) and sublingual immunotherapy (SLIT), require high patient adherence to be successful. In the literature, numbers describing adherence vary widely; this investigation compares these two routes of therapy directly.
methodsAll data were retrieved from the patient data management system of a center for dermatology, specific allergology, and environmental medicine in Germany. All 330 patients (aged 13-89 years) included in this study had commenced AIT between 2003 and 2011, thus allowing a full 3-year AIT cycle to be considered for each investigated patient.
resultsIn this specific center, SCIT was prescribed to 62.7% and SLIT to 37.3% of all included patients. The total dropout rate of the whole patient cohort was 34.8%. Overall, SLIT patients showed a higher dropout rate (39.0%) than did SCIT patients (32.4%); however, the difference between these groups was not significant. Also, no significant difference between the overall dropout rates for men and for women was observed. A Kaplan-Meier curve of the patient collective showed a remarkably high dropout rate for the first year of therapy.
conclusionThe analysis presented in this single-center study shows that most patients who discontinue AIT do so during the first year of therapy. Patients seem likely to finish the 3-year therapy cycle if they manage to adhere to treatment throughout the first year. Strategies for preventing nonadherence in AIT, therefore, need to be developed and standardized in future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.